Further studies investigating the cardiac effects of incretin analogues and comparison of GLP-1R agonists and dual GLP-1R/GIPR agonists are needed to better understand the potential benefits and risks of incretin analogue therapy in heart failure. Here, GLP1R is linked to heart failure.